Neuralstem, Inc. (Neuralstem) is engaged in development and commercialization of treatments based on our human neuronal stem cells and our small molecule compounds. Neuralstem's technology enables the production of neural stem cells of the brain and spinal cord in commercial quantities and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glial cells. Neuralstem also maintains the ability to generate stable human neural stem cell lines suitable for systematic screening of large chemical libraries. The Company is developing products using technology, including Cell Therapy and Small Molecule Pharmaceutical Compounds. The Company�s products include NSI-566 and NSI � 189.